secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103975
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports updated Phase 1b data for tegoprubart; eGFR ~68 at 12 months, predicted 5-year graft survival >96%
--------------------------------------------------------------------------------

- On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².
- Preliminary abbreviated iBox score -4.11 (on-treatment) vs -2.98 historical CNI; predicts 5-year graft survival >96%.
- No deaths, graft loss, drug-related tremor, or new-onset diabetes; six rejection episodes (18.8%), all successfully treated.
- Patients who remained on tegoprubart after rejection had mean eGFR ~73 mL/min/1.73m² at 12 months; switched to tacrolimus had ~34.
- Topline results from Phase 2 BESTOW trial comparing tegoprubart to tacrolimus expected in November 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/0000950170-25-103975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/eldn-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer